Equities research analysts predict that Sol Gel Technologies Ltd (NASDAQ:SLGL) will announce sales of $520,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Sol Gel Technologies’ earnings, with estimates ranging from $150,000.00 to $1.00 million. Sol Gel Technologies posted sales of $50,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 940%. The business is scheduled to issue its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Sol Gel Technologies will report full-year sales of $3.58 million for the current financial year, with estimates ranging from $1.41 million to $6.62 million. For the next year, analysts forecast that the business will report sales of $8.73 million, with estimates ranging from $6.11 million to $12.37 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Sol Gel Technologies.
Sol Gel Technologies (NASDAQ:SLGL) last announced its earnings results on Thursday, March 21st. The company reported ($1.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.82). The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.05 million. Sol Gel Technologies had a negative net margin of 20,190.54% and a negative return on equity of 58.33%.
Shares of Sol Gel Technologies stock opened at $7.94 on Monday. The company has a market cap of $150.44 million, a P/E ratio of -4.41 and a beta of 0.91. Sol Gel Technologies has a 52 week low of $5.41 and a 52 week high of $9.96.
Several institutional investors have recently made changes to their positions in the stock. Delek Group Ltd. raised its holdings in shares of Sol Gel Technologies by 2.7% during the first quarter. Delek Group Ltd. now owns 1,468,912 shares of the company’s stock valued at $9,895,000 after acquiring an additional 39,151 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $406,000. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Sol Gel Technologies by 3.3% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 47,149 shares of the company’s stock valued at $322,000 after acquiring an additional 1,508 shares in the last quarter. Raymond James & Associates raised its holdings in shares of Sol Gel Technologies by 81.2% during the first quarter. Raymond James & Associates now owns 41,060 shares of the company’s stock valued at $281,000 after acquiring an additional 18,400 shares in the last quarter. Finally, BlackRock Inc. bought a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $36,000. Institutional investors own 20.41% of the company’s stock.
About Sol Gel Technologies
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.